EVANSTON, Ill., March 8, 2022 /PRNewswire/ — Angiotensin Therapeutics Inc. (“Angiotensin” or the “Company”), a private biopharmaceutical company focused on developing novel therapies for COVID-19 and kidney disease, announced the publication of a study titled Novel soluble ACE2 protein provides lung and kidney protection in mice susceptible to deadly SARS-CoV-2 infection by Hassler et al. “We are pleased to share proof-of-concept data that the virus that causes COVID-19 can be neutralized using a novel soluble angiotensin-converting enzyme 2 (ACE2) protein that has a widened duration of action and strong binding to the viral spike receptor domain of SARS-CoV-2,” said Dr. Daniel Batllemain author of the article, professor of medicine at Northwestern University Feinberg School of Medicine and founder of “Angiotensin”. “This journal article shows a remarkable improvement in the survival of virus-infected mice that received the protein compared to those that did not,” said Dr. Jan WysockiMD, PhD, study co-author.
“Angiotensin” pursues therapeutic applications to its best ACE2 enzyme proteins. “Even if the pandemic subsides, there will continue to be many situations, namely unvaccinated people and people infected with strains resistant to other therapies; therefore, there is a need for additional approaches to fight against different variants of SARS-C0V-2 now and in the future. Our protein is effective in neutralizing all SARS-CoV2 variants tested in infected cells,” said Dr. Batlle. The study published online in JASN was performed in a biosafety level 3 facility where live virus can be used to infect mice with the virus that causes COVID-19 in humans.” This is proof that this new ACE2 protein should be effective for COVID-19 in humans” said Louise Hasslerfirst author of the article.
“We are excited to advance the necessary IND studies leading to trials in patients with COVID-19,” said Mr. Cory GuttermanActing CEO of Angiotensin Therapeutics.
About Angiotensin Therapeutics Inc.
“Angiotensin” is an emerging biopharmaceutical company spun off from Dr. by Daniel Batlle laboratory at Northwestern University in Chicago. The foundation of the Company is based on the application of variants of the natural soluble enzyme ACE2 allowing better pharmacodynamics and pharmacokinetics. Programs are progressing through preclinical development for COVID-19 and kidney disease treatments. Please consult Angiotensin Therapeutics Inc.
SOURCE Angiotensin Therapeutics